Clinical Trials Browser

Terminated × Brain Neoplasms × 30 days × Clear all

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT02565433 2026-03-16

PRAMECE

Phase NA Terminated

52 enrolled

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT06315296 2026-03-03

An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer

Phase NA Terminated

1 enrolled

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms

NCT01068782 2026-02-25

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Phase 2 Terminated

19 enrolled 10 charts

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT02942264 2026-02-23

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Phase 1/2 Terminated

53 enrolled 22 charts

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Recurrence, Gliosarcoma

Clinical Trials

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

PRAMECE

An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma